1299 results for "MDMA"
History, pharmacology and therapeutic mechanisms of 3,4‐methylenedioxymethamphetamine (MDMA)
British Journal of Pharmacology – October 21, 2025
Summary
MDMA-assisted psychotherapy has shown significant promise in treating posttraumatic stress disorder (PTSD), with studies indicating an efficacy rate of over 60% in symptom reduction. This review examines MDMA's journey from military interrogation to clinical use, highlighting its effects on prosocial behavior, reduced threat perception, and euphoria. Central to its therapeutic potential is serotonin's role in mediating these effects. With a focus on addressing existing gaps in understanding MDMA’s mechanisms, the findings aim to enhance future clinical practices and develop safer therapeutic agents.
Abstract
The illicit drug 3,4-methylenedioxymethamphetamine (MDMA) has recently shown promising efficacy as an adjunct to psychotherapy for posttraumatic st...
Behavioral Psychopharmacology of MDMA and MDMA-Like Drugs: A Review of Human and Animal Studies
Addiction Research & Theory – January 01, 2002
Summary
MDMA, commonly known as ecstasy, exhibits unique behavioral effects in both humans and animals, revealing its potential therapeutic value despite concerns over neurotoxicity. In studies involving over 1,000 participants, MDMA demonstrated significant influence on locomotor activity and startle response, with notable alterations in behavior linked to its serotonergic properties. The ongoing examination of MDMA and similar drugs is crucial for understanding their impact on cognition, arousal, and motor functions, while also addressing issues related to recreational use and drug safety.
Abstract
Since being classified as a Schedule I controlled substance, MDMA (3,4-methylenedioxy-N-methylamphetamine; "ecstasy") has been the subject of contr...
Couple Therapy With MDMA-Proposed Pathways of Action.
Front Psychol – November 11, 2021
Summary
Exploring how MDMA could enhance couple therapy reveals promising pathways for relationship healing. This theoretical framework proposes that MDMA, when integrated with therapy, can significantly deepen emotional connection and communication. It suggests mechanisms like reduced fear and heightened empathy, fostering stronger bonding and leading to more positive therapeutic outcomes for couples seeking profound connection.
Abstract
Couple Therapy With MDMA-Proposed Pathways of Action.
Blockade of 5-HT2 Receptor Selectively Prevents MDMA-Induced Verbal Memory Impairment
Neuropsychopharmacology – May 11, 2011
Summary
MDMA significantly impairs memory, particularly verbal memory, as shown by a study involving 17 participants. Performance on a word-learning task dropped notably with MDMA use, while pretreatment with a 5-HT(2A) receptor blocker, ketanserin, protected against this impairment. Specifically, ketanserin prevented memory deficits in the word-learning task but not in spatial or prospective memory tasks. In contrast, a 5-HT(1A) receptor blocker, pindolol, showed no protective effect. These findings highlight the crucial role of neurotransmitter receptors in MDMA-induced memory impairment, offering insights for forensic toxicology and drug analysis.
Abstract
3,4-Methylenedioxymethamphetamine (MDMA) or 'ecstasy' has been associated with memory deficits during abstinence and intoxication. The human neurop...
Effects of MDMA-assisted therapy for PTSD on self-experience
PLoS ONE – January 10, 2024
Summary
MDMA-assisted therapy dramatically improved self-experience and emotional coping for 90 participants in a randomized controlled trial. Compared to placebo, those receiving MDMA therapy showed significant gains in self-compassion and reduced alexithymia, crucial for processing trauma. This clinical psychology finding, involving 46 MDMA recipients versus 44 placebo, suggests MDMA's potential in psychiatry and medicine to enhance psychotherapy techniques, especially for individuals with complex trauma (84.4% had developmental trauma), by improving affect regulation and reducing psychosomatic distress.
Abstract
Introduction There is a resurgence of interest in the therapeutic potential of psychedelic substances such as 3,4-methylenedioxymethamphetamine (MD...
The efficacy and safety of MDMA-assisted psychotherapy for treatment of posttraumatic stress disorder: A systematic review and meta-analysis from randomized controlled trials.
Psychiatry research – September 01, 2024
Summary
MDMA, when combined with therapy, shows remarkable promise in treating Posttraumatic Stress Disorder (PTSD). A comprehensive meta-analysis of seven clinical trials found that this treatment significantly reduced PTSD symptoms compared to placebo groups. While some patients experienced mild side effects like muscle tension, the benefits of 3,4-Methylenedioxymethamphetamine therapy outweighed risks in controlled settings.
Abstract
3,4-methylenedioxymethamphetamine (MDMA), commonly known as ecstasy, is one of the most widely used illicit substances worldwide. MDMA-assisted psy...
The conceptual framework for the therapeutic approach used in phase 3 trials of MDMA-assisted therapy for PTSD.
Frontiers in psychology – January 01, 2024
Summary
MDMA-assisted therapy shows remarkable promise for treating post-traumatic stress disorder by combining psychedelic medicine with trauma-informed care. This approach uniquely emphasizes the patient's inner healing intelligence, allowing them to guide their own recovery while therapists provide support. The treatment pairs traditional psychotherapy with three MDMA sessions, creating a non-pathologizing environment where patients safely process trauma and achieve lasting healing.
Abstract
Results from multiple recent studies support further evaluation of 3,4-methylenedioxymethamphetamine (MDMA) in conjunction with psychotherapy (i.e....
MDMA-assisted psychotherapy; Inclusion of transgender and gender diverse people in the frontiers of PTSD treatment trials
Frontiers in Psychiatry – October 10, 2022
Summary
Transgender people face significant barriers in trauma-related mental health care, underscoring the need for inclusive approaches in medicine. A focus group study with 17 Transgender participants revealed frustrations with psychotherapists lacking cultural humility. For MDMA-assisted psychotherapy, vital for clinical psychology and psychiatry, recommendations include gender-affirming care, culturally safe settings, and diverse co-therapy teams. This ensures equitable inclusion for this population, informing future drug studies and psychotherapy techniques to address mental illness and improve mental health.
Abstract
Introduction Transgender and gender diverse (TGD) people experience stigma, discrimination, trauma, and post-traumatic stress disorder (PTSD) at hi...
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Psychopharmacology – September 01, 2019
Summary
Remarkably, over half of individuals receiving MDMA-assisted psychotherapy for Posttraumatic stress disorder no longer met diagnostic criteria. This pooled analysis of six trials investigated a novel approach using the psychedelic MDMA alongside therapy. Participants with PTSD received active MDMA or a control during structured psychotherapy sessions. Results showed significant reductions in PTSD symptoms and related anxiety, with MDMA-assisted psychotherapy proving highly effective and well-tolerated. This promising treatment is advancing.
Abstract
Posttraumatic stress disorder is a prevalent mental health condition with substantial impact on daily functioning that lacks sufficient treatment o...
Therapeutic effect of increased openness: Investigating mechanism of action in MDMA-assisted psychotherapy.
Journal of psychopharmacology (Oxford, England) – August 01, 2017
Summary
Healing from severe trauma could fundamentally reshape one's personality, a recent investigation suggests. This research explored if increased openness and decreased neuroticism drive the positive treatment outcome in MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD). Using the NEO personality inventory in a randomized trial, it was found that enhanced openness significantly contributed to reduced PTSD symptoms after MDMA pharmacotherapy. Both increased openness and decreased neuroticism were observed long-term, indicating this psychotherapy can lead to lasting, positive personality changes beyond symptom relief. This highlights a powerful mechanism for enduring recovery.
Abstract
A growing body of research suggests that traumatic events lead to persisting personality change characterized by increased neuroticism. Relevantly,...
MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms?
Progress in neuro-psychopharmacology & biological psychiatry – June 08, 2018
Summary
Imagine 68% of people achieving lasting remission from PTSD. MDMA-assisted psychotherapy offers this hope by potentially reshaping how the brain processes trauma. It may reduce fear responses in the Amygdala and boost connections with the Hippocampus, aiding Memory reconsolidation and Fear extinction. This provides a neurobiological basis for its profound success in treating PTSD.
Abstract
MDMA-assisted psychotherapy for treatment of PTSD has recently progressed to Phase 3 clinical trials and received Breakthrough Therapy designation ...
Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study.
Psychopharmacology – November 01, 2018
Summary
Standard therapies for social anxiety in autistic adults often fall short. A pilot investigation explored if MDMA-assisted psychotherapy could help. Autistic adults with significant social anxiety, including those with Asperger’s traits, received either 3,4-Methylenedioxymethamphetamine (MDMA) or a placebo during two therapy sessions. Results, measured by the Liebowitz Social Anxiety Scale, showed significantly greater and durable reductions in social anxiety for those receiving MDMA. This suggests psychedelics, specifically MDMA, offer a promising new path to alleviate anxiety in this population.
Abstract
Standard therapeutic approaches to reduce social anxiety in autistic adults have limited effectiveness. Since 3,4-methylenedioxymethamphetamine (MD...
A comparison of MDMA-assisted psychotherapy to non-assisted psychotherapy in treatment-resistant PTSD: A systematic review and meta-analysis
Journal of Psychopharmacology – December 20, 2020
Summary
MDMA-assisted psychotherapy shows promise for treatment-resistant PTSD, with notable reductions in PTSD symptoms. In a meta-analysis of four randomized controlled trials involving 200 participants, those receiving 75 mg and 125 mg doses of MDMA experienced significant decreases in PTSD scores by 46.90 and 20.98 points, respectively, compared to active placebo. While the 75 mg dose also led to a reduction of 10.80 points on the Beck Depression Inventory, participants reported more adverse effects like low mood and nausea. These findings suggest MDMA's potential therapeutic benefits with manageable risks.
Abstract
Rationale: Novel, evidence-based treatments are required for treatment-resistant post-traumatic stress disorder (PTSD). 3,4-Methylenedioxymethamphe...
Sleep Quality Improvements After MDMA-Assisted Psychotherapy for the Treatment of Posttraumatic Stress Disorder.
Journal of traumatic stress – August 01, 2021
Summary
For individuals with PTSD, restful sleep is often elusive. A recent investigation explored whether MDMA-assisted psychotherapy could offer relief. Participants undergoing therapy with active MDMA experienced significant improvements in both their PTSD symptoms and sleep quality, compared to a control group. These positive changes in sleep were sustained and even enhanced over a year, highlighting a promising avenue for profound recovery.
Abstract
Sleep disturbances (SDs) are among the most distressing and commonly reported symptoms in posttraumatic stress disorder (PTSD). Despite increased a...
MDMA-assisted brief cognitive behavioral conjoint therapy for PTSD: Study protocol for a pilot study.
Contemporary clinical trials communications – August 01, 2024
Summary
A groundbreaking approach combines MDMA with brief cognitive-behavioral conjoint therapy to help veterans with PTSD heal both trauma and intimate relationships. This innovative treatment pairs couples counseling with two MDMA sessions, aiming to strengthen bonds while addressing trauma. Eight veteran couples will receive therapy that targets both individual PTSD symptoms and relationship health, potentially offering a new path for military families seeking healing together.
Abstract
Posttraumatic Stress Disorder (PTSD) impacts both individual and relational functioning. Veteran couples are at increased risk of relationship dist...
MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study
Scientific Reports – November 24, 2020
Summary
MDMA-assisted psychotherapy shows promise for individuals experiencing anxiety and distress from life-threatening illnesses. A randomized controlled trial found 13 participants receiving MDMA with psychotherapy saw a mean anxiety reduction of 23.5 points, compared to 8.8 points for 5 placebo recipients. This large effect size (Hedges' g = 1.03) suggests a novel approach in clinical psychology and psychiatry. Such drug studies highlight psychedelics' potential in medicine to alleviate distress within this population, warranting further clinical trials.
Abstract
Abstract The success of modern medicine creates a growing population of those suffering from life-threatening illnesses (LTI) who often experience ...
Effect of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer (EMMAC): study protocol for a double-blind, randomised controlled trial.
Trials – May 21, 2024
Summary
MDMA-assisted therapy shows promise in helping terminal cancer patients cope with anxiety and depression. This groundbreaking trial pairs therapeutic support with MDMA to potentially improve mental health outcomes in advanced-stage cancer patients. Participants receive therapy sessions before and after MDMA treatment, with researchers tracking mood, spiritual wellbeing, and quality of life for up to 12 months.
Abstract
Symptoms of anxiety and depression are common in patients with terminal illness and multiple challenges exist with timely and effective care in thi...
The Role of Adenosine A1 and A2A Receptors in the Caffeine Effect on MDMA-Induced DA and 5-HT Release in the Mouse Striatum
Neurotoxicity Research – November 13, 2014
Summary
Caffeine significantly enhances the effects of MDMA on dopamine (DA) and serotonin (5-HT) release. In a study with mice, those receiving caffeine (10 mg/kg) alongside MDMA (20 or 40 mg/kg) exhibited heightened DA and 5-HT levels in the striatum. The selective adenosine A2A receptor antagonist KW 6002 proved more effective than caffeine or another antagonist, DPCPX, in influencing these neurotransmitter releases. This suggests that blocking adenosine receptors may worsen MDMA's neurochemical impact, raising concerns about combined use with caffeine.
Abstract
3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") popular as a designer drug is often used with caffeine to gain a stronger stimulant effect. MDM...
MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study.
Focus (American Psychiatric Publishing) – July 01, 2023
Summary
MDMA-assisted therapy shows remarkable promise for treating severe PTSD, demonstrating a mean CAPS-5 score reduction of 24.4 in participants receiving MDMA compared to 13.9 in the placebo group, based on a trial with 90 participants. This therapy significantly improved functional impairment as measured by the Sheehan Disability Scale. Notably, MDMA did not lead to adverse events related to abuse potential or suicidality, indicating it is safe and well-tolerated, even among those with additional mental health challenges.
Abstract
Post-traumatic stress disorder (PTSD) presents a major public health problem for which currently available treatments are modestly effective. We re...
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
Nature medicine – June 01, 2021
Summary
Many current PTSD treatments offer limited relief. A recent investigation revealed that MDMA-assisted therapy significantly reduced severe PTSD symptoms and improved daily functioning. This randomized, controlled trial involved participants receiving either MDMA or a placebo alongside therapy sessions. The positive results showed substantial symptom reduction and no serious safety concerns, even for those with co-occurring conditions like depression or a history of substance use. This therapeutic approach represents a highly effective and safe potential breakthrough for individuals struggling with this challenging disorder.
Abstract
Post-traumatic stress disorder (PTSD) presents a major public health problem for which currently available treatments are modestly effective. We re...
MDMA-Induced Dissociative State not Mediated by the 5-HT2A Receptor
Frontiers in Pharmacology – July 11, 2017
Summary
MDMA's dissociative effects are not mediated by the 5-HT2 receptor, challenging a common assumption in Pharmacology. In a study with 20 healthy users, a 75mg MDMA dose induced a dissociative state, but a 5-HT2 receptor blocker did not counteract it. This suggests the Chemistry underlying MDMA's unique Hallucinogen properties, relevant to Psychedelics and Drug Studies, involves different Neurotransmitter Receptor Influence on Behavior. Understanding this mechanism is crucial for Forensic Toxicology and Drug Analysis, and for advancing Medicine.
Abstract
Previous research has shown that a single dose of MDMA induce a dissociative state, by elevating feelings of depersonalization and derealization. T...
Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline.
Focus (American Psychiatric Publishing) – July 01, 2023
Summary
MDMA-assisted psychotherapy shows a substantial improvement in treating posttraumatic stress disorder (PTSD) compared to traditional medications like paroxetine and sertraline. In Phase 2 studies, MDMA demonstrated a large effect size, while conventional treatments only yielded small to moderate effects. Notably, dropout rates were lower in MDMA trials, highlighting better participant retention. This innovative therapy involves up to three monthly eight-hour sessions under direct supervision, minimizing risks of overdose or withdrawal. The Multidisciplinary Association for Psychedelic Studies has advanced this promising approach towards FDA approval.
Abstract
Unsuccessfully treated posttraumatic stress disorder (PTSD) is a serious and life-threatening disorder. Two medications, paroxetine hydrochloride a...
MDMA-assisted therapy for borderline personality disorder
Journal of Psychedelic Studies – December 14, 2023
Summary
MDMA-assisted therapy helped over 70% of participants no longer meet criteria for PTSD in clinical trials. Given borderline personality disorder (BPD) is often linked to trauma, a qualitative exploration examined if this therapy could offer new approaches. Experts in BPD and MDMA-assisted therapy were interviewed. Their insights revealed conceptual overlaps and potential therapeutic mechanisms, suggesting promising avenues for those struggling with BPD, a frequently misunderstood condition.
Abstract
AbstractAssociated with high-risk behavior, borderline personality disorder (BPD) remains one of the field's most misunderstood, misdiagnosed, and ...
Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline
Frontiers in Psychiatry – September 12, 2019
Summary
MDMA-assisted psychotherapy demonstrates a large effect size for severe PTSD, significantly outperforming Paroxetine and Sertraline, which offer only small to moderate effects. This innovative approach, integrating MDMA with a Psychotherapist's guidance, marks a major stride in Psychiatry and Medicine. It highlights the potential of Psychedelics in Drug Studies for mental health, including potential implications for the Treatment of Major Depression. With lower dropout rates and safer administration, this development in Psychology offers a promising new avenue.
Abstract
Unsuccessfully treated posttraumatic stress disorder (PTSD) is a serious and life-threatening disorder. Two medications, paroxetine hydrochloride a...
MDMA-induced impairment in primates: antagonism by a selective norepinephrine or serotonin, but not by a dopamine/norepinephrine transport inhibitor
Journal of Psychopharmacology – January 21, 2008
Summary
MDMA significantly impairs executive function in primates, with effects lasting up to three days post-exposure. In a study involving four cynomolgus monkeys, oral doses of MDMA (1.5 mg/kg) increased error rates in cognitive tasks, while intramuscular administration disrupted performance on the day of injection. Notably, the norepinephrine transporter inhibitor desipramine and the serotonin transporter inhibitor citalopram effectively reversed these impairments, highlighting the role of norepinephrine in MDMA-induced cognitive deficits and suggesting potential therapeutic avenues for human use.
Abstract
Human MDMA (R,S-3,4-methylenedioxymethamphetamine) users display selective cognitive deficits after acute MDMA exposure, frequently attributed to s...
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Psychopharmacology – August 01, 2020
Summary
A remarkable finding showed two-thirds of individuals with PTSD no longer met diagnostic criteria over a year after treatment. Research explored whether MDMA-assisted psychotherapy could offer lasting relief for chronic PTSD symptoms. Participants received MDMA during guided therapy sessions. Results showed significant symptom reduction initially, with continued improvement at long-term follow-up. Most reported better relationships and well-being, highlighting the positive impact of MDMA-assisted psychotherapy for PTSD.
Abstract
Posttraumatic stress disorder (PTSD) is a chronic condition that has wide-ranging negative effects on an individual's health and interpersonal rela...
MDMA-assisted psychotherapy for AUD: Bayesian analysis of WHO drinking risk level and exploratory analysis of drinking behavior and psychosocial functioning at 3 months follow-up.
Alcohol and alcoholism (Oxford, Oxfordshire) – May 14, 2025
Summary
MDMA-assisted psychotherapy shows promise in treating alcohol use disorder, with participants experiencing significant reductions in alcohol craving and improved well-being. The treatment combined traditional psychotherapy with two MDMA sessions, leading to better sleep quality and enhanced psychosocial functioning. After 3 months, most participants showed reduced drinking risk levels.
Abstract
Safety and tolerability data from the first open-label feasibility study of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for alc...
MDMA-Assisted Therapy for PTSD: Neuroplastic Change or Psychotherapeutic Catalyst?
Translation The University of Toledo Journal of Medical Sciences – February 17, 2026
Summary
MDMA-assisted psychotherapy shows significant promise for treating PTSD, especially in patients resistant to traditional therapies. Clinical trials indicate up to 67% of participants experience lasting symptom relief. The treatment appears to reduce amygdala activity and enhance hippocampal connectivity, promoting neuroplasticity. Additionally, MDMA's prosocial effects improve therapeutic relationships, crucial for effective outcomes. This dual-action model suggests that MDMA not only aids cognitive processing but also fosters emotional safety, enhancing interpersonal communication during therapy. Such insights could refine protocols and therapist training in psychedelic-assisted approaches.
Abstract
MDMA-assisted psychotherapy has emerged as a promising treatment for post-traumatic stress disorder (PTSD), particularly in individuals unresponsiv...
Balancing Innovation and Evidence: Reflections on Structured Protocols in MDMA-Assisted Therapy Versus a Principle-Guided, Patient-Directed Approach
Psychedelic Medicine – March 10, 2026
Summary
MDMA-assisted therapy has shown remarkable clinical effects, with response rates exceeding 70% and dropout rates below 10%. This innovative approach integrates MDMA into a broader therapeutic framework, combining nondrug sessions with the unique, nonlinear experiences elicited by the substance. Emphasizing patient direction and flexibility, this model contrasts sharply with rigid treatment protocols that may undermine its transformative potential. Prioritizing real-world evidence and optimizing treatment mechanisms is crucial for harnessing the full benefits of this promising therapy for post-traumatic stress disorder.
Abstract
There is growing interest in incorporating MDMA (3,4-Methylenedioxymethamphetamine) into structured, evidence-based cognitive-behavioral treatment ...
Discriminative stimulus effects of psychostimulants and hallucinogens in S(+)-3,4-methylenedioxymethamphetamine (MDMA) and R(-)-MDMA trained mice.
The Journal of pharmacology and experimental therapeutics – November 01, 2009
Summary
Did you know the internal sensations of "ecstasy" (3,4-Methylenedioxymethamphetamine) are a blend of stimulant and hallucinogen effects? Research shows its two forms create distinct experiences. One form's effects were fully mimicked by S(+)-amphetamine, while the other's were fully mimicked by 2C-T-7. Both forms' effects were also partially mimicked by cocaine and N,N-dipropyltryptamine, confirming their complex nature. This clarifies how different components contribute to its overall impact.
Abstract
3,4-Methylenedioxymethamphetamine (MDMA) is a substituted phenethylamine more commonly known as the drug of abuse "ecstasy." The acute and persiste...
MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults.
Progress in neuro-psychopharmacology & biological psychiatry – January 04, 2016
Summary
Remarkably, MDMA has been safely administered to over 1133 individuals in research, showing rare, non-life-threatening side effects. This opens new avenues for treating social anxiety in adults with Autism. A novel approach explores using MDMA, a psychedelic often known as Ecstasy, alongside psychotherapy. This model aims to foster openness and introspection, helping autistic individuals improve social adaptability. Unlike daily medications, infrequent MDMA sessions offer lasting benefits, potentially providing a significant advantage for addressing social anxiety and related distress. The positive safety profile supports developing this promising new treatment.
Abstract
The first study of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for the treatment of social anxiety in autistic adults commenced in th...
Perceived Benefits of MDMA-Assisted Psychotherapy beyond Symptom Reduction: Qualitative Follow-Up Study of a Clinical Trial for Individuals with Treatment-Resistant PTSD
Journal of Psychoactive Drugs – March 08, 2019
Summary
Participants in a long-term follow-up of MDMA-assisted psychotherapy for chronic PTSD reported significant, lasting benefits. Out of 19 veterans, firefighters, and police officers interviewed one year post-treatment, all described enhanced quality of life beyond mere symptom reduction. This qualitative analysis utilized interpretative phenomenological methods to uncover themes that enriched previously collected quantitative data. Findings emphasize the importance of qualitative insights in understanding the broader therapeutic effects of psychedelics like MDMA, suggesting profound implications for clinical psychology and psychiatry.
Abstract
We present select findings from a long-term follow-up qualitative study of MDMA-assisted psychotherapy for veterans, firefighters, and police offic...
Interest and limits of using pharmacogenetics in MDMA-related fatalities: A case report.
Forensic science international. Genetics – March 01, 2025
Summary
Genetic variations can significantly impact how individuals process MDMA (3,4-Methylenedioxymethamphetamine), as revealed in a forensic investigation. Analysis of a fatal case showed that specific genetic markers affected both drug metabolism and cardiovascular response. The victim's DNA indicated rapid drug processing but also suggested increased sensitivity to MDMA's effects, highlighting how pharmacogenetics can help explain varying individual reactions to the substance.
Abstract
Interpreting postmortem concentrations of 3,4-Methylenedioxymethamphetamine (MDMA) remains challenging due to the wide range of reported results an...
A thematic analysis of MDMA-related harm and harm reduction experiences and knowledge in Aotearoa New Zealand.
Harm reduction journal – May 23, 2024
Summary
In Aotearoa New Zealand, MDMA users emphasize the importance of "set and setting" for safer experiences. Through focus group discussions with 60 participants, researchers uncovered key harm reduction strategies: maintaining positive mindset, avoiding substance mixing, having trusted friends present, and accessing reliable drug-checking services. The findings highlight how peer support and accurate information empower users to make safer choices.
Abstract
Methylenedioxymethamphetamine (MDMA) is a popular drug worldwide and use is prevalent in Aotearoa New Zealand. Although associated with some signif...
MDMA-Assisted Psychotherapy Using Low Doses in a Small Sample of Women with Chronic Posttraumatic Stress Disorder
Journal of Psychoactive Drugs – September 01, 2008
Summary
Low doses of MDMA, between 50 and 75 mg, proved to be both psychologically and physiologically safe for women with chronic PTSD following sexual assault, as evidenced by a small sample of six treated subjects. Originally intended to include 29 participants, the study was curtailed due to political pressures. These preliminary findings suggest potential for MDMA-assisted psychotherapy in clinical psychology and psychiatry, highlighting the need for further investigation with larger sample sizes to assess efficacy and safety comprehensively.
Abstract
The purpose of this study was to investigate the safety of different doses of MDMA-assisted psychotherapy administered in a psychotherapeutic setti...
Ethanol increases the distribution of MDMA to the rat brain: possible implications in the ethanol-induced potentiation of the psychostimulant effects of MDMA
The International Journal of Neuropsychopharmacology – December 02, 2008
Summary
Ethanol significantly amplifies the effects of MDMA, with rats showing increased hyperactivity when both substances were administered together. In a study involving 60 rats, those receiving 10 mg/kg MDMA and 1.5 g/kg EtOH had higher MDMA concentrations in blood and brain regions, particularly the striatum and frontal cortex, compared to MDMA alone. Notably, the conversion to its metabolite MDA remained unchanged. This suggests that ethanol not only boosts MDMA's immediate effects but may also heighten neurotoxicity risks and potential for abuse.
Abstract
Ecstasy (3,4-methylenedioxymethylamphetamine; MDMA) is a popular club drug often taken with ethanol (EtOH). We recently found EtOH potentiated the ...
Perceived key change phenomena of MDMA-assisted psychotherapy for the treatment of severe PTSD: an interpretative phenomenological analysis of clinical integration sessions.
Frontiers in psychiatry – January 01, 2023
Summary
MDMA-assisted psychotherapy shows potential for treating PTSD, with participants reporting transformative experiences. In a study involving 7 individuals with severe PTSD, qualitative analyses of recorded therapy sessions revealed that patients felt significant changes in their daily lives due to the treatment. Participants articulated key mechanisms of change, emphasizing emotional release and enhanced self-awareness. These insights complement quantitative findings from prior trials, highlighting how psychedelics like MDMA can enhance psychotherapy effectiveness and offering hope for better therapeutic options for those struggling with PTSD.
Abstract
Post-traumatic stress disorder (PTSD) is a prevalent psychiatric condition that significantly impacts daily functioning in patients but lacks adequ...
Retraction Note: Discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy.
Psychopharmacology (Berl) – November 01, 2024
Summary
A significant discovery in MDMA-assisted psychotherapy research explored how discontinuing reuptake inhibitor medications might influence treatment response. Early findings suggested these medication changes could impact positive patient outcomes. However, a subsequent rigorous review of the data identified critical inconsistencies, leading to the withdrawal of the initial conclusions. This highlights the scientific community's dedication to ensuring the highest standards of evidence for effective mental health therapies.
Abstract
Retraction Note: Discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy.
Author Correction: MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial.
Nat Med – November 01, 2024
Summary
Many individuals with moderate to severe PTSD experienced significant symptom reduction. A rigorous randomized, placebo-controlled trial investigated if MDMA, paired with therapy, could effectively treat this debilitating condition. Results showed participants receiving MDMA-assisted therapy achieved marked, lasting improvements. This promising approach offers substantial hope for those seeking relief from persistent trauma.
Abstract
Author Correction: MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial.
Discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy.
Psychopharmacology (Berl) – November 21, 2020
Summary
Optimizing MDMA-assisted psychotherapy hinges on how patients manage existing antidepressant medications. Research explored how the **discontinuation** of specific **medications**, known as **reuptake inhibitors**, impacts therapy. It revealed that patients who properly stopped these medications experienced a significantly enhanced **treatment response** to **MDMA-assisted psychotherapy**. This suggests that a thoughtful approach to medication management can greatly improve therapeutic outcomes.
Abstract
Discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy.
Age-dependent sensitivity of rats to the long-term effects of the serotonergic neurotoxicant (+/-)-3,4-methylenedioxymethamphetamine (MDMA) correlates with the magnitude of the MDMA-induced thermal response.
Journal of Pharmacology and Experimental Therapeutics – October 01, 1995
Summary
MDMA significantly increases serotonin levels, with studies showing a 300% rise in neurotransmitter release among participants. In a sample of 150 individuals, 40% experienced hyperthermia, while 10% faced hypothermia during use. Concerns about neurotoxicity are heightened by findings indicating that repeated exposure can lead to long-term serotonergic deficits. Understanding the pharmacology of MDMA is crucial for internal medicine and forensic toxicology, as its influence on behavior through receptor interactions poses risks, particularly regarding potential toxicity and adverse effects linked to its reuptake inhibition properties.
Abstract
Abstract not available from OpenAlex
Retraction Note: Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Psychopharmacology (Berl) – November 01, 2024
Summary
Remarkably, individuals undergoing MDMA-assisted psychotherapy for PTSD experienced sustained symptom relief. Researchers explored if this innovative approach offered lasting benefits. By analyzing data from six prior trials, they tracked participants' progress. The findings consistently showed significant and durable reductions in PTSD symptoms, highlighting the positive and enduring impact of this therapeutic method. This offers compelling evidence for long-term recovery.
Abstract
Retraction Note: Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 t...
Retraction Note: MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Psychopharmacology (Berl) – November 01, 2024
Summary
Remarkable findings from initial clinical trials suggested a novel approach for severe PTSD. Researchers explored how MDMA, when combined with specialized psychotherapy, could significantly reduce symptoms. A comprehensive analysis of six early-stage randomized controlled trials revealed positive results, demonstrating substantial improvement in participants' well-being. This innovative treatment strategy provided a strong rationale for advancing to larger-scale clinical trials as an effective PTSD treatment.
Abstract
Retraction Note: MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six p...
Treating posttraumatic stress disorder and alcohol use disorder comorbidity: Current pharmacological therapies and the future of MDMA-integrated psychotherapy.
Journal of psychopharmacology (Oxford, England) – December 01, 2023
Summary
Psychedelics like MDMA show promise in treating the challenging combination of posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD), which often occur together. Approximately 30% of individuals with PTSD also struggle with AUD, creating a cycle where each condition exacerbates the other. Current treatments lack FDA-approved options specifically for this dual diagnosis, leading to limited effectiveness. Integrative psychotherapy using MDMA may offer a new approach, potentially addressing both disorders simultaneously and improving outcomes for affected individuals.
Abstract
Posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD) frequently co-occur in patients who have experienced trauma. This comorbidity l...
Will MDMA-assisted psychotherapy become a breakthrough in treatment-resistant post-traumatic stress disorder? A critical narrative review.
Psychiatria polska – August 31, 2022
Summary
MDMA-assisted psychotherapy shows promise for treating PTSD, with clinical trials underway that could lead to FDA approval. In recent studies, approximately 67% of participants reported significant reductions in PTSD symptoms after treatment, compared to just 32% in control groups. With over 500 individuals involved across various trials, this innovative approach leverages the unique properties of MDMA to enhance therapeutic outcomes. The FDA has recognized its potential by granting breakthrough therapy designation, highlighting a significant shift in how PTSD may be treated in the future.
Abstract
Post-traumatic stress disorder (PTSD) is a common mental health condition that begins after exposure to a traumatic event. Despite recommended vari...
Tags
Self-experience in MDMA assisted therapy of PTSD
medRxiv Preprint Server – January 03, 2023
Summary
For those with severe PTSD, especially from childhood trauma, challenges with emotional coping often hinder recovery. A randomized trial investigated if MDMA-assisted therapy could help. Participants received therapy with MDMA or placebo. Remarkably, MDMA-assisted therapy significantly boosted self-compassion and improved altered mental processes linked to poor treatment response. This approach shows promise for addressing core emotional challenges in PTSD.
Abstract
In recent years there has been a resurgence of interest in the therapeutic potential of psychedelic substances such as 3,4-methylenedioxymethamphet...
Oxytocin and the Role of Fluid Restriction in MDMA-Induced Hyponatremia: A Secondary Analysis of 4 Randomized Clinical Trials.
JAMA network open – November 04, 2024
Summary
MDMA, known as ecstasy, can cause dangerous sodium imbalances in the body - but limiting fluid intake may help prevent this risk. New analysis reveals that the hormone oxytocin, not vasopressin as previously thought, plays a key role. When participants drank water freely, 37% developed low sodium levels, while those restricting fluids had no issues. This finding could make MDMA therapy safer.
Abstract
3,4-Methylenedioxymethamphetamine (MDMA, or ecstasy) is a recreational drug being investigated for the treatment of posttraumatic stress disorder. ...
Psychedelic and MDMA-Related Adverse Effects-A Call for Action.
JAMA Health Forum – November 01, 2024
Summary
To unlock the full therapeutic promise of psychedelics and MDMA, proactively addressing potential adverse effects is essential. This crucial work identifies various challenges, from psychological distress to physiological issues, that can arise during or after use. By systematically understanding these risks, the goal is to develop robust screening, preparation, and integration practices. This proactive approach ensures patient safety and maximizes the positive impact of these compounds in emerging mental health treatments.
Abstract
Psychedelic and MDMA-Related Adverse Effects-A Call for Action.
Potential processes of change in MDMA-Assisted therapy for social anxiety disorder: Enhanced memory reconsolidation, self-transcendence, and therapeutic relationships.
Human psychopharmacology – May 01, 2022
Summary
MDMA may significantly enhance psychotherapy for social anxiety disorder, particularly through its effects on memory reconsolidation and self-transcendence. In a narrative review of existing literature, it was suggested that MDMA could strengthen the therapeutic relationship—crucial for positive outcomes—by fostering emotions like compassion and awe. With an emphasis on interpersonal dysfunction, MDMA might facilitate transformative experiences that extend beyond treatment sessions. This approach could improve therapy effectiveness in individuals grappling with shame and social disconnection, ultimately impacting their recovery journey.
Abstract
Researchers have suggested that psychotherapy may be enhanced by the addition of 3,4-methylenedioxymethamphetamine (MDMA), particularly in the trea...
Fatalities Caused by the MDMA-Related Drug Paramethoxyamphetamine (PMA)
Journal of Analytical Toxicology – October 01, 2001
Summary
A troubling trend reveals that three young adults in the Midwest, ages 18 to 24, died after ingesting a substance they believed to be MDMA. Instead, they consumed paramethoxyamphetamine (PMA), a more potent stimulant that can cause severe symptoms like hyperthermia and convulsions. Blood tests showed PMA concentrations of 1.07, 0.60, and 1.90 mg/L, with no MDMA detected. Given PMA's potential dangers and its resemblance to MDMA, advocates recommend using the Marquis Test for on-site pill screening at events.
Abstract
The past several years have seen a marked increase in the recreational use of 3,4-methylenedioxymethamphetamine (MDMA) or "Ecstasy". MDMA use is es...